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Abstract
Background: Antithrombin and recombinant human thrombomodulin (rhTM) are individually reported to improve survival in
sepsis-induced disseminated intravascular coagulation (DIC). However, continuing controversy exists as to which agent is
superior and whether concomitant therapy is superior to individual administration. Methods: This post hoc analysis included
adult patients with sepsis-induced DIC from a nationwide multicenter registry database in Japan. We categorized patients into 4
groups: patients who received (1) individual administration of antithrombin, (2) individual administration of rhTM, (3) both, and (4)
neither. In-hospital mortality was compared between every 2 groups among the 4 groups by Cox proportional hazards model
adjusted with propensity scores. Results: In total, 1432 patients with sepsis-induced DIC were included. Although both
antithrombin and rhTM were associated better outcome compared with no anticoagulants, mortality benefits were similar
between each individual anticoagulant. Similarly, no significant difference in mortality was detected between individual adminis-
trations and concomitant therapy. Conclusion: Antithrombin and rhTM might have comparable efficacy in reducing mortality in
patients with sepsis; however, concomitant therapy appeared to offer no additional survival benefit.
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Background
Sepsis almost invariably complicates deranged blood coagula-
tion disorders ranging from subclinical activation to distinct
systemic dysfunction of blood coagulation, that is, dissemi-
nated intravascular coagulation (DIC). Sepsis-induced DIC
plays a crucial role in inducing multiple organ dysfunction
syndrome and is associated with an increased risk of death.1,2
Although the management of DIC should be directed primarily
at the treatment of the underlying disorders, it is often difficult
to control coagulation disorders in patients with sepsis-induced
DIC. Therefore, anticoagulant therapy is considered to be
effective as supportive therapy against DIC to improve clinical
outcomes.3 Actually, much evidence based on previous obser-
vational studies and post hoc subgroup analyses of randomized
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controlled trials suggests that anticoagulant therapies may
improve mortality in patients with sepsis-induced DIC.4-11
However, we have little knowledge about which anticoagu-
lant is the most effective for sepsis-induced DIC. Antithrombin
and recombinant human thrombomodulin (rhTM) are com-
monly used anticoagulant agents for sepsis-induced DIC and
are often coadministered. According to the recent studies based
on the Diagnosis Procedure Combination (DPC) database in
Japan, 37.7% of patients treated with antithrombin were
reported to receive coadministration of rhTM, and 45.9% of
patients treated with rhTM were reported to receive coadminis-
tration of antithrombin.12,13 Both agents were reported to be
associated with lower risk of death in sepsis-induced DIC by
recent large-scale observational studies10,11; however, due to a
lack of definitive clinical evidence, continuing controversy
exists about which agent is superior and whether concomitant
therapy is superior to individual administration.
The present study was designed to compare safety and effi-
cacy between the individual administration of antithrombin or
rhTM and to evaluate whether the concomitant administration
of both agents over individual administration could reduce the
rate of death in sepsis-induced DIC.
Materials and Methods
Study Population
This investigation was a post hoc subgroup analysis of a nation-
wide multicenter retrospective cohort study conducted in 42
intensive care units (ICUs) in Japan between January 2011 and
December 2013.10 Patients were consecutively included in the
registry if they were equal to or older than 18 years and diag-
nosed with having severe sepsis or septic shock according to
the Sepsis-1 criteria proposed by the American College of
Chest Physicians/Society of Critical Care Medicine (ACCP/
SCCM) consensus conference in 1991.14 Among them, we
included patients with sepsis-induced DIC in this study. The
patients were considered to have DIC if they fulfilled the Japa-
nese Association for Acute Medicine (JAAM) DIC criteria on
the day of ICU admission.15
The exclusion criteria were as follows: use of warfarin/acet-
ylsalicylic acid/thrombolytic therapy before study entry; his-
tory of fulminant hepatitis, decompensated liver cirrhosis, or
other serious liver disorder; history of hematologic malignant
disease; other conditions associated with coagulation disorder;
treatment with any chemotherapy at study entry; and patients
with missing data for main analysis.
This study followed the principles of the Declaration of
Helsinki and was approved by the institutional review board
of each participating hospital. Because of the anonymous
and retrospective nature of this study, the board of each
hospital waived the need for informed consent. This study
was registered with the University Hospital Medical Infor-
mation Network Clinical Trial Registry (UMIN-CTR ID:
UMIN000012543).
Sepsis Definitions
In this study, “sepsis” meant severe sepsis and septic shock in
the conventional criteria (sepsis-1). Severe sepsis was defined
according to the definitions set and revised by the ACCP/
SCCM consensus conference in 1991: combination with a
suspected or proven infection, 3 or more signs of systemic
inflammation, and more than 1 organ dysfunction. Septic shock
was also defined according to the ACCP/SCCM consensus in
1991 as sepsis-induced hypotension persisting despite adequate
fluid resuscitation and requiring catecholamine infusions to
improve hemodynamic status.14
Data Collection
Patients were followed up until hospital discharge or death. A
case report form was developed for the study, and the following
information was obtained: age, sex, scores for illness severity
on the day of ICU admission, source of ICU admission,
preexisting comorbidities, primary source of infection, and
therapeutic interventions such as immunoglobulin, low-dose
steroid, renal replacement therapy, and low-dose heparin for
prophylaxis against deep vein thrombosis (DVT). We evalu-
ated the severity of illnesses according to the Acute Physiology
and Chronic Health Evaluation II score and the Sequential
Organ Failure Assessment (SOFA) score at study entry. The
primary outcome measure was all-cause in-hospital mortality.
We also recorded bleeding complications as secondary out-
comes. Bleeding complications included the occurrence of
intracranial hemorrhage, transfusion requirements related to
bleeding, and bleeding requiring surgical intervention.
Patient Categorization
To compare the efficacy and safety between antithrombin,
rhTM, and concomitant therapy with both agents, we categor-
ized the study patients into 4 treatment groups: (1) patients who
received individual administration of antithrombin (antithrom-
bin group), (2) patients who received individual administration
of rhTM (rhTM group), (3) patients who received both antith-
rombin and rhTM (concomitant group), and (4) patients who
received neither agent (nonanticoagulant group). For study pur-
poses, we compared the primary and secondary outcomes
between every 2 groups among these 4 study groups.
Statistical Analysis
Due to the retrospective nature of the study, there were baseline
imbalances between the groups; therefore, an adjusted analysis
was performed using propensity scores.16-18 The propensity
score for the likelihood of undergoing therapies that patients
actually received was calculated using multivariable logistic
regression analysis including age, sex, disease severity, source
of ICU admission, medical history of severe conditions, new
organ dysfunctions, types and volume of ICUs, primary source
of infection, causal microorganisms, and other therapeutic
interventions as covariates. The detailed combinations of the
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variables are described in Table S1. We compared the in-
hospital mortality between every 2 groups among the 4 groups
by Cox proportional hazards model adjusted with inverse prob-
ability of treatment weighting (IPTW) using the propensity
score. For secondary outcomes of bleeding complications, we
compared one group to every other group by logistic regression
analysis adjusted by IPTW estimation.
Descriptive statistics are summarized as group medians with
the first and third quartiles for continuous variables and frequen-
cies with percentages for categorical variables. Univariate dif-
ferences between groups were assessed using the Kruskal-Wallis
test or w2 test. All hypotheses were 2-sided, and a P value of <.05
indicated statistical significance. All statistical analyses were
conducted using STATA Data Analysis and Statistical Software
version 14.0 (StataCorp, College Station, Texas).
Results
Study Population and Categorizations
The patient flow diagram is shown in Figure 1. During the
study period, 3195 consecutive patients fulfilled the inclusion
criteria and were registered in the J-SEPTIC DIC registry data-
base. After excluding 1763 patients without DIC and 352
patients who met at least 1 exclusion criterion, we included
1432 patients as the final study cohort. Among them, 271
(20.6%) patients received individual administration of antith-
rombin, 221 (14.4%) patients received individual administra-
tion of rhTM, 316 (20.6%) patients received both antithrombin
and rhTM, and 624 (40.7%) received neither agent.
Baseline Characteristics
Table 1 shows the baseline characteristics of the study popula-
tion categorized by the presence and types of anticoagulant
therapy. There were no significant differences in age and sex
distribution between the groups. Baseline disease severity indi-
cated by SOFA and JAAM DIC scores were significantly dif-
ferent between the 4 groups and tended to be lower in the
nonadministration group. We also found the percentage of con-
comitant use of therapeutic interventions other than anticoagu-
lants, such as immunoglobulin, low-dose steroid, renal
replacement therapy, and low-dose heparin for prophylaxis
against DVT to be significantly different between the groups.
Mortality
The main results in this study using Cox proportional hazards
analyses adjusted by propensity score to evaluate the difference
in in-hospital mortality between every 2 groups among the 4
groups are shown in Table 2. We also show the propensity
score-adjusted survival curves for the 4 groups in Figure 2. The
adjusted hazard ratios (HRs) of in-hospital mortality for the
antithrombin group and rhTM group compared to the nonanti-
coagulant group were 0.68 (95% confidence interval [CI]:
0.51-0.91; P ¼ .008) and 0.72 (95% CI: 0.52-0.99; P ¼
.044), respectively, indicating significant survival benefits
associated with all 3 types of anticoagulant therapies. In con-
trast, we detected no significant difference in in-hospital mor-
tality between the antithrombin and rhTM groups (adjusted
HR: 0.95, 95% CI: 0.60-1.49; P ¼ .748) or between the indi-
vidual administration groups and the concomitant group (HR:
1.03, 95% CI: 0.65-1.66; P ¼ .826 for antithrombin vs conco-
mitant, and HR: 1.09, 95% CI: 0.66-1.82; P¼ .625 for rhTM vs
concomitant).
Bleeding Complications
We summarized the findings for differences in the risk of
bleeding complications between every 2 groups among the 4
Figure 1. Patient flow diagram. APACHE indicates Acute Physiology and Chronic Health Evaluation; DIC, disseminated intravascular coagu-
lation; rTM, recombinant human thrombomodulin; SCCM/ACCP, Society of Critical Care Medicine/American College of Chest Physicians;
SOFA, Sequential Organ Failure Assessment.
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groups in Table 3. We observed a significantly higher risk of
bleeding complications in the antithrombin group compared to
the nonanticoagulant group, whereas the rhTM group was not
associated with a higher risk of bleeding complications com-
pared to the nonanticoagulant group. We also found that the
risk of bleeding complications in concomitant therapy was not
significantly different compared to that for the individual
administration of each agent.
Discussion
Recently, multiple lines of evidence have clarified that antic-
oagulant therapy against sepsis-induced DIC can improve mor-
tality.3,8,10,11,19 Antithrombin and rhTM are the most
commonly used agents against sepsis-induced DIC, and these
2 agents are often coadministered in Japan. However, a con-
tinuing controversy remains about whether 1 agent is superior
to the other and whether concomitant therapy with these 2
agents is superior to individual administration. The current
propensity score-adjusted study provided the evidence that
(1) there was no difference in survival benefit between the
individual administration of antithrombin or rhTM, (2) conco-
mitant administration of antithrombin and rhTM showed
no additional beneficial effects or interactions over the
individual administration of these agents, and (3) concomitant
Table 1. Baseline Characteristics of the 4 Groups.a
Variable
Nonanticoagulant Antithrombin rhTM Concomitant
P Valuen ¼ 624 n ¼ 271 n ¼ 221 n ¼ 316
Patient characteristics
Age, years 73 (63-81) 72 (63-80) 72 (62-78) 72 (62-80) .424
Sex, male 353 (56.6%) 152 (56.1%) 122 (55.2%) 171 (54.1%) .907
Illness severity
APACHE II score 23 (17-30) 24 (17-29) 23 (17-29) 24 (18-30) .887
SOFA score 9 (7-13) 11 (8-13) 10 (8-13) 12 (9-14) <.001
JAAM DIC score 5 (4-6) 6 (4-7) 6 (5-7) 6 (5-8) <.001
ISTH overt-DIC score 4 (3-5) 4 (4-5) 4 (4-5) 5 (4-6) <.001
Source of ICU admission <.001
Emergency department 307 (49.2%) 133 (49.1%) 82 (37.1%) 134 (42.4%)
Ward 156 (25.0%) 74 (27.3%) 45 (20.4%) 80 (25.3%)
Other hospital 161 (25.8%) 64 (23.6%) 94 (42.5%) 102 (32.3%)
Preexisting comorbidities
Immunocompromised 63 (10.1%) 19 (7.0%) 31 (14.0%) 39 (12.3%) .055
Chronic kidney disease 71 (11.4%) 21 (7.7%) 13 (5.9%) 16 (5.1%) .003
Chronic heart failure 28 (4.5%) 17 (6.3%) 16 (7.2%) 9 (2.8%) .079
Chronic respiratory disorder 28 (4.5%) 10 (3.7%) 5 (2.3%) 7 (2.2%) .223
Liver insufficiency 7 (1.1%) 2 (0.7%) 3 (1.4%) 4 (1.3%) .909
Site of infection .067
Abdomen 212 (34.0%) 113 (41.7%) 67 (30.3%) 107 (33.9%)
Lung 131 (21.0%) 46 (17.0%) 45 (20.4%) 51 (16.1%)
Urinary tract 123 (19.7%) 44 (16.2%) 54 (24.4%) 77 (24.4%)
Bone/soft tissue 56 (9.0%) 35 (12.9%) 25 (11.3%) 41 (13.0%)
Central nervous system 19 (3.0%) 6 (2.2%) 8 (3.6%) 7 (2.2%)
Other/unknown 83 (13.3%) 27 (10.0%) 22 (10.0%) 33 (10.4%)
Therapeutic interventions
Immunoglobulin 96 (15.4%) 127 (46.9%) 78 (35.3%) 196 (62.0%) <.001
Low-dose steroid 121 (19.4%) 81 (29.9%) 75 (33.9%) 120 (38.0%) <.001
Renal replacement therapy 154 (24.7%) 115 (42.4%) 90 (40.7%) 177 (56.0%) <.001
Low-dose heparin 28 (4.5%) 38 (14.0%) 8 (3.6%) 17 (5.4%) <.001
Interventions for source control 235 (37.7%) 141 (52.0%) 99 (44.8%) 153 (48.4%) <.001
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; DIC, disseminated intravascular coagulation; ICU, intensive care unit; ISTH, Interna-
tional Society of Thrombosis and Hemostasis; JAAM, Japanese Association for Acute Medicine; rhTM, recombinant human thrombomodulin; SOFA, Sequential
Organ Failure Assessment.
aData are presented as the median (first and third quartiles) for continuous variables and number (%) for categorical variables. Differences between groups were
assessed using the Kruskal-Wallis or w2 test.
Table 2. Propensity Score-Adjusted Comparison of In-hospital
Mortality.
Treatment Reference HR 95% CI P Value
Antithrombin vs Nonanticoagulant 0.68 0.51-0.91 .008
rhTM vs Nonanticoagulant 0.72 0.52-0.99 .044
Concomitant vs Nonanticoagulant 0.66 0.47-0.91 .012
Antithrombin vs rhTM 0.95 0.60-1.49 .748
Antithrombin vs Concomitant 1.03 0.65-1.66 .826
rhTM vs Concomitant 1.09 0.66-1.82 .625
Abbreviations: CI, confidence interval; HR, hazard ratio; rhTM, recombinant
human thrombomodulin.
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administration of these agents caused no additional adverse
effects over those of individual administration.
Differences in Mortality Between Antithrombin and rhTM
Multiple evidence based on previous observational studies and
post hoc subgroup analyses of randomized controlled trials
suggested the association of survival benefits with anticoagu-
lant therapies for sepsis-induced DIC.4-11 The current study
also demonstrated significant reductions in mortality in all 3
groups of anticoagulant therapies compared to the nonanticoa-
gulant group.
However, there has been a great deal of controversy about
which agent, antithrombin or rhTM, is more effective in
improving patient outcomes because only a few studies have
investigated the superiority of 1 agent over the other. Our study
showing no significant difference in mortality between antith-
rombin and rhTM agreed with a recent large-scale observa-
tional study based on the Japanese DPC database,20 and these
lines of evidence provide a robust indication that these 2 agents
offer almost comparable survival benefit for patients with
sepsis-induced DIC.
Significance of Concomitant Administration
of Anticoagulants
In our study population, 316 patients received the concomitant
administration of antithrombin and rhTM, which was equal to
53.8% of the total number of patients who received antithrom-
bin and 58.8% of the total number of patients who received
rhTM. Another database in Japan reported by Tagami et al
showed that 37.7% of the sepsis-induced DIC patients who
received antithrombin were coadministered rhTM, and 45.9%
of the sepsis-induced DIC patients who received rhTM were
coadministered antithrombin.12,13 These findings might reflect
the current Japanese clinical situation in which the concomitant
administration of these 2 agents was widely performed as adju-
tant management for sepsis-induced DIC. Therefore, clinical
evidence to evaluate the superiority of concomitant adminis-
tration over individual administration is strongly required.
Antithrombin exerts its anticoagulant properties by control-
ling the activity of thrombin and a large number of coagulation
factors including factors VIIa, IXa, Xa, XIa, and XIIa.21 In
contrast, rhTM forms a high-affinity complex with circulating
thrombin and activates protein C, which inactivates coagula-
tion factors Va and VIIIa, thereby suppressing further thrombin
generation.22 Previous studies reported that these 2 indepen-
dent anticoagulant pathways neither affect nor disturb each
other.23 Therefore, the concomitant administration of antith-
rombin and rhTM could possibly exert additive and synergistic
anticoagulant effects. Actually, several animal studies demon-
strated that concomitant therapy with antithrombin and rhTM
could modulate cell death, decrease the circulating levels of
damage-associated molecular patterns, and lead to reduced
organ damage and mortality.24,25
Nevertheless, despite these theoretical advantages of the
concomitant administration of antithrombin and rhTM, the effi-
cacy of concomitant therapy remains a topic of controversy
because of a lack of definitive clinical evidence.26,27 We have
provided the best evidence so far that the survival benefit asso-
ciated with concomitant therapy was almost comparable to that
of the individual administration of antithrombin or rhTM in the
clinical situation. However, we cannot offer a clear explanation
for why concomitant therapy was not associated with a greater
effect on mortality despite the line of pathophysiological
advantage reported by past basic studies. One possible reason
might be that the individual administration of these agents
already has sufficient efficacy to improve the patient’s condi-
tion, so that any additional benefit from coadministration of the
other agent might be concealed.
Adverse Events
Bleeding was the most significant adverse event associated
with anticoagulant therapy. In this study, we showed that the
individual administration of antithrombin was associated with
a higher risk of bleeding complications compared to nonuse
of an anticoagulant. These findings agreed with those of
previous studies showing an association between antithrombin
Figure 2. Adjusted estimated survival curves according to the types
and presence of anticoagulant therapy. rhTM indicates recombinant
human thrombomodulin.
Table 3. Propensity Score-Adjusted Comparison of Bleeding
Complications.
Treatment Reference OR 95% CI P Value
Antithrombin vs Nonanticoagulant 2.10 1.30-3.41 .002
rhTM vs Nonanticoagulant 1.10 0.60-2.01 .749
Concomitant vs Nonanticoagulant 2.12 1.17-3.86 .013
Antithrombin vs rhTM 1.91 1.06-3.44 .031
Antithrombin vs Concomitant 0.99 0.55-1.78 .973
rhTM vs Concomitant 0.52 0.26-1.03 .061
Abbreviations: CI, confidence interval; OR, odds ratio; rhTM, recombinant
human thrombomodulin.
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administration and an increased risk of bleeding complica-
tions.28,29 Therefore, anticoagulant therapy including antith-
rombin should be administered only inpatients who can be
expected to receive sufficient survival benefits despite the
potentially increased risk of bleeding.
Limitations of This Study
Because of the retrospective study design, baseline character-
istics and therapeutic interventions, including the concomitant
use of low-dose heparin for prophylaxis of DVT, were different
between the 4 groups. Therefore, we developed a propensity
score approach to cope with the nonrandomized effect of antic-
oagulant therapies. However, it is hard to remove the effects of
observed confounding completely because multiple unmea-
sured variables may account for the outcome differences
observed in this study. Further multicenter prospective rando-
mized trials are therefore required to gather definitive evidence
of the difference in clinical outcomes between individual and
concomitant anticoagulant therapy against sepsis-induced DIC.
Conclusion
The present study using the multicenter nationwide J-Septic
DIC registry in Japan suggested that individual administration
of antithrombin or rhTM had comparable efficacy in reducing
mortality, but concomitant administration of these 2 agents
might offer no additional survival benefit. Our findings raise
some concerns about the routine use of concomitant anticoa-
gulant therapy against sepsis-induced DIC.
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